Recent News
Read ArticleA pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.
Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological https://t.co/scmfAAE9XA
Dr. John Cush @RheumNow ( View Tweet)
#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/h0oe3WksK1
Dr. John Cush @RheumNow ( View Tweet)
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/L5XRcIxl5s
Dr. John Cush @RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/31IRNXckym
Dr. John Cush @RheumNow ( View Tweet)
RHEUM SURVEY> When treating NON-RENAL lupus, is a drug with a "lupus nephritis indication" more likely to be used? Answer here >> https://t.co/1KridYM9n8 https://t.co/WiBhdKRxik
Dr. John Cush @RheumNow ( View Tweet)
Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.
Read Article
EULAR26: Updates in SLE and APS
EurekAlert!
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
Read Article
Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists.
New educational content will release https://t.co/ZOQQuZinQd
Dr. John Cush @RheumNow ( View Tweet)
Bundibugyo virus disease (BVD) outbreak in the Congo in 2026. BV is an orthoebolavirus (not Ebola virus) species. Of the 2351 reported, 505 (22%)confirmed by PCR & 19% died. Sxs: Most 20-39 yrs, F>M, Fever (74%), GI & diarrhea (67%), anorexia, Abd pain (37%). HA (42%), SOB (34%), https://t.co/yYSmPjuiZW
Dr. John Cush @RheumNow ( View Tweet)
Where are we with Biomarkers in Rheumatoid Arthritis?
Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and https://t.co/ggoWx8yumZ
Dr. John Cush @RheumNow ( View Tweet)
B cell Targeting in SLE
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ
Dr. John Cush @RheumNow ( View Tweet)
RHEUM SURVEY> Do you prefer a lupus drug if it has a lupus nephritis indication (when your treating non-renal SLE)? Answer here >> https://t.co/1KridYM9n8 https://t.co/zIqNB5Mc0O
Dr. John Cush @RheumNow ( View Tweet)
NEJM on anti-CD19 CAR-T cell therapy in B cell lymphoma - 38 pts w/ refractory NHL (24 lg B-cell, 1414 follicular lymphoma) Rx w/ CTL019. 10-yr survival = 32% w/ large B-cell & 47w/ follicular lymphoma; Persistent neutropenia 5%, & 2nd primary cancer seen in 21%. B-cell aplasia https://t.co/CPKvunGZxl
Dr. John Cush @RheumNow ( View Tweet)
Self-Directed Cognitive Behavioral Therapy for Chronic Pain
Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?
2026 Guidelines for the Treatment of Axial Spondyloarthritis
ACR
New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults, alongside a newly developed companion guideline focused specifically on juvenile axial spondyloarthritis.
Read Article
Redefining axial spondyloarthritis
An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."
https://t.co/C1Kei8AU3h https://t.co/lspQYyEFHa
Dr. John Cush @RheumNow ( View Tweet)
U Maryland study found that 5-minutes of proximal intercessory prayer (PIP) — in-person prayer offered by a trained volunteer — significantly reduced pain and anxiety in primary care patients compared to a music control group. 180 pain pts (pain >4/10) w/ > 2 pt reductions at 2 & https://t.co/k4JiQvyC31
Dr. John Cush @RheumNow ( View Tweet)
Up to 80% of Brucellosis has MSK Sxs (half in the spine/SI). CDC reports in the USA 2010–2024 1,796 confirmed and probable cases - 61% reported travel (80% Intl travel). Most exposures consumed unpasteurized dairy products or undercooked meat 73%], 62% had animal contact and 40% https://t.co/Njpf71jwKd
Dr. John Cush @RheumNow ( View Tweet)
4-week, proof-of-concept, PBO-controlled RCT Rx 30 Depression pts w/ either PBO or tocilizumab. No improvement by day 14, but over time TCZ pts improved depressive Sxs & severity, fatigue, anxiety, & QOL. Remission seen in 54% vs 31%, favoring TCZ. https://t.co/FpdZJikf8C https://t.co/IaKP3JXARa
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Generic Tofacitinib (6.26.2026)
DERM on RheumNow (June 2026)-
Do You Zoster Vaccinate? (6.19.2026)
RheumNow EULAR 2026 Rheumatology Round Up
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
